Condition: Atopic Dermatitis · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
This description comes directly from the study's public registry record.
Pengcheng Lei · +86 18501252185 · pengcheng.lei@innocarepharma.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Male or female subjects between 18 and 75 years of age. 2. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year 3. Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable. 4. Subjects must meet the following criteria for disease activity: * Eczema Area and Severity Index (EASI) score ≥ 16 ; * (Body Surface Area )BSA affected by AD ≥ 10% ; * (validated Investigator's Global Assessment-AD)vIGA-AD score ≥3 ; * Baseline weekly average of daily Worst Pruritus NRS ≥ 4. 5. Women of childbearing potential (WOCBP) and Men must agree 5\. Women of childbearing potential (WOCBP) and Men must agree to contraception. 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Lack of response or inadequate response to prior treatment with any JAK inhibitor for AD. 2. Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions. 3. Pregnant or breastfeeding females. 4. History of any clinically major diseases, with the exception of atopic dermatitis. 5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ICP-332 or participate in this study.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| The Second Affiliated Hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
| Capital Medical University Affiliated Beijing Chaoyang Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Capital Medical University Affiliated Beijing Friendship Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tongren Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing Traditional Chinese Medicine Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| The Affiliated Union Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
+ 50 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.